Therapeutic area intelligence for Stroke Recovery with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Companies: 1

Companies

Astellas Pharma →

Assets

ASP2246 →

Recent signals(1)

ClinicalJuly 3, 2026

Astellas initiates first-in-human trial of ASP2246 for post-stroke movement disorders

Astellas Pharma has launched a first-in-human study of ASP2246 targeting movement problems following stroke.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.